Amgen's goal to reduce US cardiovascular events by 2030

Amgen Cardiovascular Ambition

Amgen’s bold vision to halve major cardiovascular events in the US by 2030 continues to advance with renewed vigor, marked by strategic collaborations, pipeline innovations, and an adaptive ecosystem approach. Since reaffirming this ambitious target at the 2026 Leerink Global Healthcare Conference, Amgen has not only deepened its commitment to transforming cardiovascular care but also navigated a shifting competitive and regulatory landscape with strategic agility.

Expanded TrumpRx Partnership Now Includes GSK: A Health Equity Milestone

A landmark development in 2026 is the expansion of Amgen’s TrumpRx partnership to include pharmaceutical powerhouse GlaxoSmithKline (GSK). This tri-party collaboration aims to broaden access, affordability, and culturally tailored patient support for cardiovascular therapies, with a particular focus on minority and underserved populations disproportionately affected by cardiovascular disease.

Key enhancements brought by GSK’s inclusion include:

Culturally tailored education initiatives designed to elevate cardiovascular health literacy among diverse communities, recognizing the critical role of culturally sensitive messaging in improving outcomes.
Expanded patient support services, such as personalized navigation, adherence coaching, and financial counseling, to reduce barriers throughout the patient journey.
Broadened affordability programs that alleviate out-of-pocket costs, addressing the economic challenges that often hinder therapy initiation and persistence.

This expanded TrumpRx effort exemplifies Amgen’s core strategic pillar of health equity, emphasizing that multi-stakeholder collaborations are essential to tackling social determinants of health and closing persistent care gaps. The partnership’s holistic approach—integrating education, access, and affordability—aligns with growing industry recognition that effective cardiovascular care must extend beyond the clinic.

Four Strategic Pillars Driving Amgen’s Cardiovascular Ecosystem

At the 2026 Leerink Conference, Amgen’s leadership framed their 2030 goal as a north star guiding a patient-centric, multi-stakeholder ecosystem anchored by four evolving strategic pillars:

Integrated Digital Health Platforms:
Amgen continues to scale AI-driven risk stratification and remote monitoring technologies across major health systems. These tools enable precise, personalized intervention timing and foster sustained patient engagement, accelerating the reduction of cardiovascular events.
Health Equity and Access Programs:
The TrumpRx expansion with GSK stands as a flagship example of intensified efforts to dismantle financial and educational barriers, deploying culturally sensitive outreach tailored to historically underserved populations.
Value-Based Care Leadership:
Amgen is expanding value-based contracts with payers, increasingly linking reimbursement to meaningful cardiovascular outcomes such as reductions in myocardial infarction and stroke. This model aligns incentives across providers and payers, underscoring Amgen’s leadership in outcome-driven healthcare.
Real-World Evidence and Transparency:
A commitment to openly sharing updated cardiovascular event metrics—derived from large-scale electronic health records and claims data—fosters payer and provider confidence, enabling continuous refinement of care protocols.

Pipeline Innovations: Poised to Transform Cardiovascular Care

Amgen’s cardiovascular pipeline remains robust and strategically diversified, with several late-stage candidates set to reshape clinical practice:

Lp(a) Antisense Oligonucleotide:
Expected pivotal readouts in late 2027 target elevated lipoprotein(a), a genetically driven and largely unaddressed cardiovascular risk factor. Amgen expresses cautious optimism that, combined with statins and PCSK9 inhibitors, this therapy could substantially reduce residual cardiovascular risk.
Inflammation and Thrombosis Modulators:
New agents focusing on inflammatory pathways and thrombosis risk are advancing, potentially broadening protection beyond traditional lipid lowering.
Cardiometabolic Portfolio Diversification:
Responding to competitive pressures, Amgen is expanding beyond GLP-1 receptor agonists to include non-GLP-1 cardiometabolic therapies, addressing the complex interplay between metabolic and cardiovascular risks.

Navigating Intensifying Market and Regulatory Pressures

While Amgen’s strategic positioning is strong, the company faces evolving external challenges and responds with proactive measures:

Biosimilar PCSK9 Competition:
Accelerated FDA approvals of biosimilar PCSK9 inhibitors have intensified pricing pressures. Amgen counters this through enhanced patient support programs and real-world evidence demonstrating the clinical and economic differentiation of its therapies.
Medicare GLP-1 Pilot and Safety Monitoring:
A Medicare pilot program expanding GLP-1 therapy access introduces new market dynamics. Concurrent FDA safety reviews of rare bone fracture risks linked to some GLP-1 receptor agonists have tempered prescribing trends, influencing uptake.
Eli Lilly’s Employer-Focused GLP-1 Push:
The competitive landscape is further complicated by Eli Lilly’s aggressive employer-targeted initiatives, which could unlock new GLP-1 demand but also intensify competition for cardiometabolic market share. This initiative may expand patient access broadly, potentially reshaping prescribing patterns and payer negotiations.
Heightened Payer Expectations:
Payers increasingly demand reimbursement models tied to measurable patient outcomes. Amgen’s growing portfolio of value-based contracts and transparent data sharing align closely with these expectations, positioning the company as a leader in outcome-based cardiovascular care.

Financial Performance and Investor Sentiment: Growth Coupled with Caution

Amgen recently reported quarterly earnings that surpassed expectations, propelled by strong cardiovascular product sales and optimism around pipeline prospects. This performance led to an upward revision of financial guidance through 2026, reflecting confidence in near- and mid-term growth trajectories.

However, investor sentiment remains cautiously optimistic. Analysts from firms such as Jefferies maintain Hold ratings, pointing to uncertainties around pivotal trial outcomes, biosimilar market expansion, and ongoing regulatory scrutiny as moderating factors. Minor institutional share sales and technical resistance at current price levels indicate the market is awaiting key clinical and commercial catalysts before increasing exposure.

Near-Term Watchlist: Key Milestones to Track

Several imminent events will critically influence Amgen’s cardiovascular trajectory and its 2030 vision:

Late-Stage Clinical Trial Readouts:
Pivotal data from the Lp(a) antisense oligonucleotide and inflammation/thrombosis modulator programs, expected by late 2027, will strongly affect clinical guidelines, prescribing trends, and market adoption.
Biosimilar PCSK9 Launches:
Ongoing biosimilar entries will require agile pricing and patient engagement strategies to defend market share.
Value-Based Care Program Evaluations:
Outcomes from expanded payer collaborations will determine the scalability and sustainability of value-based reimbursement models tied to cardiovascular event reductions.
Regulatory and Safety Updates:
Continued FDA reviews on GLP-1 receptor agonist safety and other emerging therapies will impact market access and prescribing dynamics.
Investor and Market Responses:
Transparent, timely dissemination of clinical and real-world evidence will be critical to maintaining investor confidence amid competitive and regulatory headwinds.

Conclusion: Positioned to Deliver Transformative Cardiovascular Impact by 2030

Amgen’s mission to halve major cardiovascular events in the US by 2030 is increasingly supported by a comprehensive ecosystem strategy, strategic partnerships, and a diversified pipeline. The expanded TrumpRx collaboration with GSK highlights a deep commitment to health equity, while advances in digital health, value-based care, and data transparency reinforce Amgen’s leadership in outcome-driven cardiovascular management.

As pivotal clinical milestones approach and market dynamics evolve—especially with emerging competitive pressures from biosimilars and Eli Lilly’s employer initiatives—Amgen’s strategic agility and ecosystem-driven model position it strongly to drive meaningful improvements in cardiovascular health and realize its transformative 2030 vision.

Sources (16)